{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Number of patients unable to achieve adequate stem cell mobilization, need to undergo one or tandem transplantation. Stem cell mobilization = A process in which certain drugs are used to cause the movement of stem cells from the bone marrow into the blood. The stem cells can be collected and stored. They may be used later to replace the bone marrow during a stem cell transplant.","groups":[{"description":"Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.\n\ncarboplatin: Days -6, -5, -4: 500mg/m2\\^/day intravenously (IV) over 60 minutes\n\netoposide: 600mg/m\\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.\n\nthiotepa: 150mg/m\\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4\n\nautologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\\< 4 x 10\\^6 CD34+ cells/kg)\n\nfilgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.","id":"OG000","title":"2 Transplants"},{"description":"Patients with Germ cell tumors who receive one transplant only.\n\nifosfamide: 2500 mg/m\\^2/day continuous infusion intravenously on Days -6, -5 and -4.\n\npaclitaxel: 225 mg/m\\^2 intravenous over 3 hours on Day -7.\n\nautologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\\< 4 x 10\\^6 CD34+ cells/kg)\n\nMesna: 2500 mg/m\\^2/day continuous infusion intravenously on Days -6, -5 and -4.\n\nfilgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.","id":"OG001","title":"1 Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.","reportingStatus":"POSTED","timeFrame":"Pre-Transplant","title":"Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells","type":"SECONDARY","unitOfMeasure":"Participants"}